+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Lymphoma Treatment Market 2019-2025

  • ID: 5129646
  • Report
  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
UP TO OFF
until Dec 31st 2021

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
Lymphoma Treatment Market Size, Share & Trends Analysis Report by Type (Hodgkin and Non-Hodgkin), By Therapy Type (Radiation therapy, Chemotherapy, and Others), By Drug Type (Adcetris, Rituxan/MabThera, Imbruvica, Keytruda, Revlimid, and Others), Forecast 2019-2025.

The global Lymphoma treatment market is anticipated to grow at a significant CAGR during the forecast period. Lymphoma is a type of cancer that begins at infection-fighting cells of the immune system called lymphocytes. The factor contributing to the growth of the market include the support provided by the government of regions such as North America and Europe to make hospitals more favorable and equipped with Lymphoma treatment essentials.

The global Lymphoma treatment market is segmented on the basis of type, therapy type, and drug type. Based on type, the market is bifurcated into Hodgkin and Non-Hodgkin Lymphoma. Based on therapy type, the market is sub-segmented into radiation therapy, chemotherapy, and others. Further, on the basis of the drug type, the market is sub-segmented into adcetris, rituxan/mabthera, imbruvica, keytruda, revlimid, and others such as opdivo. Revlimid is estimated to contribute a prominent share in 2018 and is expected to continue the same trend during the forecast period.

Geographically, the study of the global Lymphoma treatment market report covers the analysis of four major regions including North America (the US and Canada), Europe (UK, Germany, Italy, Spain, France, and Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), and the Rest of the World. Asia-Pacific is estimated to exhibit a significant growth rate in the global Lymphoma treatment market during the forecast period. The increasing geriatric population in the region drives the growth of the market. In addition, improving healthcare infrastructure further gives a boost to the regional growth of the market.

Moreover, the study of the global Lymphoma treatment market report covers the analysis of various players operating in the market. Some of the key players covered in the report include Pfizer Inc., Johnson & Johnson Services Inc., Celgene Corp., Bristol Myers Squibb Co., Takeda Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Novartis International AG, Sanofi, Seattle Genetics Inc., Teva Pharmaceutical Industries Ltd., and others. The market players are considerably contributing to the market growth by adopting various strategies including new product launch, mergers and acquisitions, and collaborations to stay competitive in the market.

Research Methodology

The market study of the Lymphoma treatment market is incorporated by extensive primary and secondary research. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.
The report is intended for the players working in Lymphoma landscape, pharmaceutical companies, drug manufacturers, medical device companies, healthcare industry, research organizations, academic institutes, government organizations, regulatory bodies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, products offered by the companies, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. Global Lymphoma Treatment Market Research and Analysis by Type
2. Global Lymphoma Treatment Market Research and Analysis by Therapy Type
3. Global Lymphoma Treatment Market Research and Analysis by Drug Type

The Report Covers
  • Comprehensive research methodology of the Lymphoma treatment market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Lymphoma treatment market.
  • Insights about market determinants which are stimulating the Lymphoma treatment market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bristol Myers Squibb Co.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography

2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations

3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Bristol-Myers Squibb Co
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Celgene Corp.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Pfizer Inc.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Johnson & Johnson Services Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Takeda Pharmaceutical Co.Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments

4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities

5. Market Segmentation
5.1. Lymphoma treatment Market by Type
5.1.1. Hodgkin
5.1.2. Non-Hodgkin
5.2. Lymphoma treatment Market by Therapy Type
5.2.1. Radiation therapy
5.2.2. Chemotherapy
5.2.3. Others (Monoclonal Antibody Therapy)
5.3. Lymphoma treatment Market by Drug Type
5.3.1. Adcetris
5.3.2. Rituxan/MabThera
5.3.3. Imbruvica
5.3.4. Keytruda
5.3.5. Revlimid
5.3.6. Others (Opdivo)

6. Regional Analysis
6.1. North America
6.1.1. US
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World

7. Company Profiles
7.1.
7.2. AbbVie Inc.
7.3. AeternaZentaris Inc.
7.4. AstraZeneca PLC
7.5. Bayer AG
7.6. Bristol Myers Squibb Co.
7.7. Cadila Pharmaceuticals Ltd.
7.8. Celgene Corp.
7.9. Eli Lilly and Co.
7.10. Epizyme, Inc.
7.11. F. Hoffmann-La Roche Ltd.
7.12. GlaxoSmithKline PLC
7.13. Johnson & Johnson Services Inc.
7.14. Merck & Co., Inc.
7.15. Novartis International AG
7.16. Pfizer Inc.
7.17. Sanofi SA
7.18. Seattle Genetics, Inc.
7.19. Spectrum Pharmaceuticals, Inc.
7.20. Takeda Pharmaceutical Co.Ltd.
7.21. Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • AbbVie Inc.
  • AeternaZentaris Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Cadila Pharmaceuticals Ltd.
  • Celgene Corp.
  • Eli Lilly and Co.
  • Epizyme, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Co.Ltd.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll